Expanding Global Biosimilar Market
Between 2010 and 2013, $95 billion in branded pharmaceutical patents will have expired, leading to significantly higher sales opportunities for those manufacturing generics and biosimilars.
Between 2010 and 2013, $95 billion in branded pharmaceutical patents will have expired, leading to significantly higher sales opportunities for those manufacturing generics and biosimilars.
Physicians at the 2015 AMA Annual Meeting passed policy calling on CMS not to withhold claim payments based on coding errors, mistakes or malfunctions in the system for two years directly following ICD-10 implementation.
These abstracts and presentations were presented 12 June at the EULAR 2015 annual meeting.
These abstracts and presentations were presented Thursday 11 June at the EULAR 2015 annual meeting.
A EULAR task force of 21 rheumatologists and radiologists from 11 countries examined 12 clinical/imaging questions and reviewed the literature to establish consensus on imaging for spondyloarthritis in practice.
EULAR 2015 started the afternoon of Wednesday June 10th.
Chikungunya is a new viral cause of fever and arthritis, especially in endemic areas like the caribbean. The chikungunya epidemic has grown significantly in the Western hemisphere with a total of 1,247,000 cases and 183 fatalities since
CVD risk is significantly augmented in gout. Choi and coworkers studied this issue using a UK general population database using an incident user cohort study with propensity score matching.
A Danish nationwide healthcare registry was used to identify newly diagnosed alcoholic cirrhosis patients between 1977 and 2010. A matched cohort analysis compared each patient with five random individuals from the population.
While many adult rheumatologists are able to lessen or withdraw DMARD and biologic therapy in adults, little is known about the success of this practice in pediatric rheumatology clinics.
The global knee implants market was USD 8.4 billion in 2011, and it's forecasted to reach USD 15 billion in 2018, with compound annual growth rate of 8.64% during 2011 to 2018. The U.S.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.